Eisai, Biogen's Alzheimer's drug Leqembi makes market debut in China
28 Jun 2024
Drug Approval
Eisai and Biogen on Friday announced the launch of Leqembi (lecanemab) in China, making the country the third market to welcome the Alzheimer's disease therapy for sale. Regulators in China approved the anti-amyloid antibody in January as a treatment for mild cognitive impairment due to Alzheimer's disease and mild Alzheimer's disease dementia.
The companies noted that Leqembi will first be launched in the private market in China, with a price of CNY 2508 ($345) per vial. In the US, the product carries an annual list price of around $26,500, while in Japan – where it was launched at the end of last year – it costs about JPY 2.98 million ($18,542) per patient per year.
Eisai said that a major Chinese medical insurance company has developed and launched a healthcare insurance plan specifically for Alzheimer's disease including partial coverage of the drug cost. Meanwhile, Eisai has created an online health platform, called Yin Fa Tong, in collaboration with JD Health, which includes a dedicated dementia module allowing virtual consultations before a face-to-face appointment, as well as referrals to hospitals where diagnostic tests can be performed before Leqembi administration.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.